<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01093859</url>
  </required_header>
  <id_info>
    <org_study_id>PB-09-001</org_study_id>
    <nct_id>NCT01093859</nct_id>
  </id_info>
  <brief_title>An Exploratory Phase 1 Microdose Study of PRX-105</brief_title>
  <official_title>An Exploratory Phase 1 Study to Assess the Safety and Pharmacokinetics of PRX-105, Administered as a Single, Microdose, Intravenous Slow Bolus Injection to Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Protalix</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Protalix</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Exploratory phase 1, first in human, open label, non-randomized, single-dose study of
      PRX-105, administered intravenously by slow bolus injection to 10 healthy volunteers. The
      objective is to evaluate the pharmacokinetic profile of PRX-105 without any significant
      physiological effect in healthy volunteers after a single, intravenous microdose
      administration.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2010</start_date>
  <completion_date type="Actual">August 2010</completion_date>
  <primary_completion_date type="Actual">May 2010</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PRX-105 plasma concentration</measure>
    <time_frame>0 to 48 hours after injection</time_frame>
    <description>Assessment of pharmacokinetics</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cardiovascular monitoring</measure>
    <time_frame>0 to 48 hours after injection</time_frame>
    <description>Cardiac safety assessment will include ECG for cardiac rhythm and anomalies, and 24 hrs Holter for QT interval evaluation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neurological examination</measure>
    <time_frame>0 to 48 hours</time_frame>
    <description>Oculomotor and ophthalmic nerves (eye movements and pupil reaction to light), muscle strength, tonus and walking</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ophthalmic evaluation</measure>
    <time_frame>0 to 8 hours</time_frame>
    <description>pupillar light reaction, accommodation, visual acuity</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Organophosphate Exposure</condition>
  <arm_group>
    <arm_group_label>PRX-105 Infusion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PRX-105</intervention_name>
    <description>Sterile solution for intravenous injection</description>
    <arm_group_label>PRX-105 Infusion</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male volunteers aged 18-45 (inclusive) years.

          -  Body Mass Index (BMI) 19 to 29 kg/m2 (inclusive) and weighing at least 60 Kg and up to
             90 kg.

          -  Non-smoking (by declaration) for a period of at least 6 months prior to screening
             visit.

          -  Blood pressure and heart rate within normal limits.

          -  Electrocardiogram (ECG) with no clinically significant abnormalities.

        Exclusion Criteria:

          -  History of significant neurological (including history of seizures or EEG
             abnormalities), renal, cardiovascular (including known structural cardiac
             abnormalities or hypertension), respiratory (asthma), endocrinological,
             gastrointestinal, hematopoietic disease, neoplasm, psychological (marked anxiety,
             tension or agitation) or any other clinically significant medical disorder, which in
             the investigator's judgment contraindicate administration of the study medication.

          -  Current / previous occupational exposure to organophosphates or pesticides.

          -  Previous receipt of any investigational butyrylcholinesterase product.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Einat Almon, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Protalix Ltd</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Tel-Aviv Sourasky Medical Center</name>
      <address>
        <city>Tel-Aviv</city>
        <zip>64239</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>September 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 24, 2010</study_first_submitted>
  <study_first_submitted_qc>March 24, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 26, 2010</study_first_posted>
  <last_update_submitted>September 4, 2012</last_update_submitted>
  <last_update_submitted_qc>September 4, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 5, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>acetylcholinesterase</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

